In a pivotal ruling, a federal judge in New Hampshire granted class-action status to a lawsuit challenging Trump's birthright citizenship order, temporarily blocking its implementation. This decision aims to protect the rights of children born in the U.S. amid ongoing legal battles.
In a groundbreaking move, Novartis has received approval for Coartem® Baby, the first malaria treatment specifically designed for newborns and young infants, addressing a critical healthcare gap in malaria-endemic regions.
Swiss authorities have approved Coartem Baby, the first malaria treatment for newborns under 11 pounds, addressing a significant health gap for vulnerable infants. This sweet cherry-flavored drug can be mixed with breast milk, making it easier to administer.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a pivotal vote, the CDC's advisory committee has recommended the use of clesrovimab, a new monoclonal antibody, for infants under eight months to combat RSV, marking a significant advancement in public health.
Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
A groundbreaking CDC study shows a dramatic decline in RSV hospitalizations for infants, with new vaccines and treatments reducing rates by up to 71%. Discover how these advancements are transforming baby care and preventing severe illness.
A recent analysis reveals a dramatic decrease in RSV-associated hospitalizations among infants aged 0-7 months during the 2024-25 season, thanks to the widespread use of maternal vaccination and nirsevimab. This significant reduction highlights the effectiveness of preventive measures and underscores the importance of early intervention.
Whooping cough cases in the U.S. have surged to alarming levels, with 8,077 cases reported in 2025, compared to just 3,847 last year. Experts warn of rising deaths among infants and link the outbreak to declining vaccination rates.
Engineers at Northwestern University have developed a groundbreaking ultra-miniature pacemaker, smaller than a grain of rice, designed for infants with congenital heart defects. This device provides a less invasive alternative to traditional pacemakers and safely dissolves after use.
